Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

283
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
283
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

579
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
579
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

1.7K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
1.7K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physical Examination Practices of Internal Medicine Residents: A Pilot Study.

Cureus·2026
Same author

Our Patients as Teachers: Adapting to Disability Our Patients as Teachers.

Journal of general internal medicine·2026
Same author

A Pilot Study of an Attachment-Based Parenting Intervention for Mandarin-Speaking Families in Canada.

Clinical child psychology and psychiatry·2025
Same author

Candida parapsilosis Fungemia in a Patient With Spinal Cord Injury on Sodium-Glucose Cotransporter-2 Inhibitor Therapy: A Case Report.

Cureus·2025
Same author

Brivaracetam for spinal cord injury-related neuropathic pain: results of a pilot double-blinded, randomized, placebo-controlled clinical trial.

Pain reports·2025
Same author

Time for an Update? Fungal Infection Trends and Practices With Mechanical Circulatory Support.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2025

Related Experiment Video

Updated: Jul 14, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K

Drug-Induced Parkinsonism: Too Many Cooks in the Kitchen.

Mark Liotta1, Harrison Bell1, Anh-Thu Vu2

  • 1Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, USA.

Cureus
|October 10, 2023
PubMed
Summary

Drug-induced parkinsonism (DIP) can mimic Parkinson's disease (PD) due to medications. Early recognition and proper diagnosis, aided by SPECT scans, are crucial for effective management of these drug-induced symptoms.

Keywords:
antidopaminergicantipsychoticsdatscandrug-induced parkinsonismiatrogenic complicationparkinson' s disease

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.6K

Related Experiment Videos

Last Updated: Jul 14, 2025

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.8K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.8K
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

7.6K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Drug-induced parkinsonism (DIP) presents with parkinsonian symptoms due to medication use.
  • DIP is frequently misdiagnosed and can be mistaken for Parkinson's disease (PD).

Observation:

  • A 64-year-old male developed parkinsonian symptoms while on atypical antipsychotics.
  • This patient's condition was initially misdiagnosed as PD.

Findings:

  • Antipsychotics and antiepileptic drugs with antidopaminergic properties are common causes of DIP.
  • (123)I-ioflupane SPECT scans can aid in differentiating DIP from PD.

Implications:

  • Healthcare providers must be vigilant for medication side effects, polypharmacy, and interactions.
  • Recognizing iatrogenic causes of parkinsonism is essential for accurate diagnosis and treatment.
  • Differentiating DIP from PD is critical for appropriate patient management and prognosis.